secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-073363
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indivior Q4 earnings beat; SUBLOCADE rev $252M (+30%); new $400M buyback; FY26 guidance reaffirmed
--------------------------------------------------------------------------------

- Q4 total net revenue $358M (+20% YoY); SUBLOCADE net revenue $252M (+30%); GAAP diluted EPS $0.79 vs $0.17
- Non-GAAP Q4 net income $107M ($0.82 diluted EPS); Adjusted EBITDA $142M (+91% YoY)
- FY 2025: revenue $1,239M (+4%), SUBLOCADE $856M (+13%); GAAP net income $210M ($1.64 EPS); adj. EBITDA $428M (+20%)
- Board authorized new $400M share repurchase program (up to 18 months) for opportunistic deployment
- FY 2026 guidance: SUBLOCADE $905M-$945M, adj. EBITDA $535M-$575M, non-GAAP opex $430M-$450M

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000119312526073363/0001193125-26-073363-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000119312526073363/d713689d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-073363

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer